LB Pharmaceuticals Presents LB-102 Cognitive Data LB-102 cognitive data presented Mar 27, 2026 could affect ~20–30% of stroke survivors and 55M dementia patients globally; follow-on randomized trials are the key catalyst.

LB Pharmaceuticals Presents LB-102 Cognitive Data: LB-102 cognitive data presented Mar 27, 2026 could affect ~20–30% of stroke survivors and 55M dementia patients globally; follow-on randomized… 👈 Read full analysis #LBPharmaceuticals #CognitiveData #DementiaResearch #StrokeSurvivors #ClinicalTrials

After a long biotech IPO lull, LB Pharma chances its arm After a promising start, IPOs all but fizzled out this year, but LB Pharma is hoping that won't stymy its chances of completing a Nasdaq listing.

#PharmaPhorum #biotech #IPO #LBPharma #LBPharmaceuticals #Nasdaqlisting #biotechIPOs #USA #drugdevelopment #LB102 #antipsychoticdrug #amisulpride #centralnervoussystem #schizophrenia #Amisulpride #clinicaldevelopment #bipolardepression #PositiveandNegativeSyndromeScale #PANSS
zurl.co/oJUIU

After a long biotech IPO lull, LB Pharma chances its arm After a promising start, IPOs all but fizzled out this year, but LB Pharma is hoping that won't stymy its chances of completing a Nasdaq listing.

After a promising start, #biotech #IPOs all but fizzled out this year, but #LBPharmaceuticals is hoping that won't stymy its chances of completing a #Nasdaq listing.

Click Subscribe #LBPharmaceuticals #IPO #Nasdaq #PharmaStocks #Investing